{
    "elements": [
        {
            "type": "table",
            "sequence_num": 1,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "RESEARCH & DEVELOPMENT SERIOUS BREACHES (Trust sponsored)"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "MEHTSOP058"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP)"
                    },
                    {
                        "text": "SOP"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "All staff"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "th12 December 2019"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "th11 December 2022"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "Service Development"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "17"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Research & Development"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Lauren Perkins, R & D Manager"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\uf0fcMEHT \u25a1 BTUH \u25a1 SUH"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Research and Development"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "05/07/2019"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Tracey Camburn R & D Director, Clinical Lead Nurse"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "26/07/2019"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "DRAG Chair's Action"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "12th December 2019"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group"
                    },
                    {
                        "text": "Date: December 2019"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "Intranet & Website"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 2,
            "data": {
                "url": "MEHTSOP058 Serious Breaches (Trust Sponsored) 1.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 3,
            "data": {
                "num_rows": 13,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Consulted With:"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Tracey Camburn"
                    },
                    {
                        "text": "R&D Co-Director/ lead research nurse"
                    },
                    {
                        "text": "04/07/2019 05/07/2019"
                    },
                    {
                        "text": "Christine Catley"
                    },
                    {
                        "text": "Senior renal research nurse"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "MEHTSOP003 SAEs (Sponsored) SOP-03- Auditing MEHTSOP005 Informed Consent MEHTSOP006 SAEs (Hosted) MEHTSOP062 Trial Master File (Sponsored) MEHTSOP061 Research Staff Training SOP-08- Role of CI, pharmacy, nuclear medicine and R&D MEHTSOP059 Amendments"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 10,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Newly created"
                    },
                    {
                        "text": "12th December 2019"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 6,
            "data": {
                "is_heading": 1,
                "text": "Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Purpose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Applicable"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Procedure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "Related documents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "References"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "Equality Impact Assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 0,
                "text": "Appendix 1 - Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 0,
                "text": "Appendix 2 - Potential GCP Breach/ Protocol Violation Form Appendix 3 - Examples of Serious Breaches"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 0,
                "text": "Appendix 4 \u2013 Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "BACKGROUND"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "This document sets out the procedures to be followed by all Mid Essex Hospital Services NHS Trust (MEHT) staff who are involved in Clinical Trials of Medicinal Products (CTIMPs) and non-CE marked Medical Devices."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "It provides guidance on how serious breaches of GCP/protocol must be identified and managed."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": "The procedures to be followed to ensure compliance with Regulation 29A of the UK Medicines for Human Use (Clinical Trials) Regulations 2004 (Statutory Instrument 2004/1031) as amended by Statutory Instrument 2006/1928, are fully detailed."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 1,
                "prefix": 1.4,
                "text": "Notification of serious breaches \u2013 29A"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 0,
                "text": "The sponsor of a clinical trial shall notify the licensing authority in writing, within 7 days of becoming aware of that breach. For example, any serious breach of:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 0,
                "prefix": 1.5,
                "text": "For the purposes of this regulation, a \u201cserious breach\u201d is a breach which is likely to affect, to a significant degree;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 0,
                "prefix": 1.6,
                "text": "These stipulations were incorporated into regulation to:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 0,
                "prefix": 1.7,
                "text": "Deviations from clinical trial protocols and GCP occur commonly in clinical trials. The majority of these instances are technical deviations that do not result in harm to the trial subjects or significantly affect the scientific value of the reported results of the trial. These cases should be documented e.g. in the Case Report Form (CRF) for the trial or Trial Master File (TMF), in order for appropriate Corrective And Preventative Actions (CAPA) to be taken. In addition, these deviations should be included and considered when the clinical study report is produced, as they may have an impact on the analysis of the data. However, not every deviation from the protocol needs to be reported to the MHRA as a serious breach. The reporting procedures for protocol violation/deviation are usually defined in the clinical trial protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 0,
                "prefix": 1.8,
                "text": "The judgement on whether a breach is likely to have a significant impact on the scientific value of the trial depends on a variety of factors including the design of the trial, the type and extent of the data affected by the breach, the overall contribution of the data to key analysis parameters, the impact of excluding the data from the analysis etc."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 0,
                "prefix": 1.9,
                "text": "It is the responsibility of the Sponsor to assess the impact of the breach on the scientific value of the trial. Anyone who is unsure whether a breach has occurred can contact the R&D Office to discuss the situation and clarify whether a breach is classed as serious (examples of possible serious breaches can be found in Appendix 3)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "PURPOSE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 0,
                "text": "\u25cf To outline procedures for identifying a potential serious breach of GCP or protocol violation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 0,
                "text": "\u25cf To describe the process for notification of serious breaches of GCP or the approved trial protocol"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 0,
                "text": "\u25cf To ensure appropriate assessments are carried out by relevant parties and fully documented"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 0,
                "text": "\u25cf To outline the role of the Research & Development in assessing all reported serious breaches and following the escalation plan"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "APPLICABLE TO"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "Any Trust employee (including those with an honorary research contract or letter of access) involved with clinical research including, but not limited to, Chief Investigators (CI), Principal Investigators (PI), Consultants, Co-Investigators, Clinical Trial Pharmacists, Research Managers, Statisticians, Research Nurses, Research Midwives, Allied Health Professionals, Trial Coordinators & Data Managers."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "RESPONSIBILITIES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "prefix": 4.1,
                "text": "All researchers must ensure all possible serious breaches are reported to the Chief Investigator (CI) immediately or as stated in protocol. For multicentre trials, any reported events by participating sites to the study coordinator should be notified to the CI."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 0,
                "prefix": 4.2,
                "text": "The Chief Investigator or delegated individual (DI) of the study shall ensure that any reported possible serious breaches are reported as stated in protocol and Trust SOPs."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 0,
                "prefix": 4.3,
                "text": "For sponsored multicentre trials, the process for identifying breaches should be provided to all participating sites at study set up. The sponsor should also ensure that adequate procedures are in place as part of the routine monitoring processes to identify potential GCP breaches."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 0,
                "text": "Research & Development Research Staff Training / MEHTSOP058/1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 1,
                "prefix": 4.4,
                "text": "For any possible serious breaches reported to the R&D Office, the RDAG/ RDAG Sub-group (Director of R&D, Assistant Director of R&D, clinical representation as required) shall be informed immediately (within 24 hours) and ensure appropriate recommendations  are  made  to  the  Chief  Investigator  regarding  further management of the breach and notification to patients if required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 0,
                "prefix": 4.5,
                "text": "The R&D Office shall also ensure that details of the breach are reported to RDAG."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 0,
                "prefix": 7.0,
                "text": "The R&D Office and the Chief Investigator shall ensure that all reported serious breaches  are  reported  to  MHRA  within   days  and  any  relevant  follow  up information is provided as soon as possible."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "PROCEDURE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 0,
                "text": "Timeframes for reporting Serious Breaches of GCP or the Trial Protocol"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 0,
                "text": "Once a possible breach of an approved trial protocol or GCP has been identified \u2013 the study team will assess the following"
            }
        },
        {
            "type": "image",
            "sequence_num": 48,
            "data": {
                "url": "MEHTSOP058 Serious Breaches (Trust Sponsored) 1.0.002.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "text": "Does the breach affect the scientific Does the breach affect the safety,  value of the trial?"
            }
        },
        {
            "type": "image",
            "sequence_num": 50,
            "data": {
                "url": "MEHTSOP058 Serious Breaches (Trust Sponsored) 1.0.003.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 0,
                "text": "physical or mental integrity of the trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "text": "subjects or the scientific value of the"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "text": "trial?"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "text": "No  No"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "text": "Yes/Unsure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 1,
                "text": "24 Hours"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "text": "This is a protocol violation/breach.  Report to R&D office immediately for  This is a protocol violation/breach. Record/report as per protocol  further guidance  Record/report as per protocol"
            }
        },
        {
            "type": "image",
            "sequence_num": 58,
            "data": {
                "url": "MEHTSOP058 Serious Breaches (Trust Sponsored) 1.0.005.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 1,
                "text": "24 hours"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 1,
                "text": "R&D to be notified of the issue immediately following the above notification; R&D to confirm whether this is a serious breach"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 1,
                "text": "Not a serious breach  Not a serious breach"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 1,
                "text": "Serious breach confirmed \u2013 R&D to"
            }
        },
        {
            "type": "image",
            "sequence_num": 63,
            "data": {
                "url": "MEHTSOP058 Serious Breaches (Trust Sponsored) 1.0.007.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 0,
                "text": "inform study team of further action and"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 0,
                "prefix": 6.0,
                "text": "recommendations from R&D"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 0,
                "text": "Research & Development Research Staff Training / MEHTSOP058/1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 0,
                "text": "CT to inform MHRA/R&D office within 7 days"
            }
        },
        {
            "type": "image",
            "sequence_num": 68,
            "data": {
                "url": "MEHTSOP058 Serious Breaches (Trust Sponsored) 1.0.008.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 0,
                "text": "CI to report to the Trust risk management team in accordance with the Risk Management Policy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 0,
                "text": "If serious breach has affected the study status and/or in breach of conditions of ethical approval, REC should also be notified"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 1,
                "prefix": 5.1,
                "text": "Identifying and Notifying Sponsor of a Serious Breach"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 0,
                "text": "5.1.1 It  is  the  responsibility  of  the  Chief  Investigator  and  Principal  Investigator(s)  to continually monitor the conduct of the clinical trial; this may be delegated to a suitably qualified or experienced member of the research team or sub-contracted to an appropriately qualified party (e.g. coordinating centre). In addition the R&D Office may audit the trial as part of their Quality Assurance procedures."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 0,
                "text": "5.1.2 If a possible protocol violation and/or GCP breach has been identified, the CI should carry out an assessment as illustrated in the flow diagram above to confirm if the event affects the safety, physical or mental integrity of the trial subject or the scientific value of the trial. If yes, this should be treated as a possible Serious Breach and should be investigated further. Immediate reporting to the R&D Office is also required. However, if the event only relates to a protocol violation, then record the event as per protocol requirements."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 1,
                "text": "5.1.3 Any potential serious breaches of GCP identified either through monitoring, audit or by other means must be reported to the R&D Office within 24 hours of the breach being identified by the study team using the form in Appendix 2. For multicentre trials, the clock starts when the event has been either identified by the sponsor or when the event has been reported to CI by the participating site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 0,
                "text": "5.1.4 If the event is considered to be a possible serious breach of GCP, then the initial reporting to the R&D Office should be carried and should provide the following information:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 0,
                "text": "1) Name of Chief Investigator and Principal Investigator at the site where the breach occurred"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 0,
                "text": "2) Full title and RD number of the clinical trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 0,
                "text": "3) An explanation of how the breach was identified"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 0,
                "text": "4) Details of the breach"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 0,
                "text": "5) Details of any immediate corrective actions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 0,
                "text": "6) Assessment of the impact the breach will have on the trial subjects and/or scientific integrity"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 0,
                "text": "5.1.5 For sponsored multicentre trials, the process for identifying breaches should be provided to all participating sites at study set up. The sponsor should also ensure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 0,
                "text": "that adequate procedures are in place as part of the routine monitoring processes to identify potential GCP breaches."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 0,
                "text": "5.1.6 If a possible breach has been reported by a PI at a participating site or identified by the sponsor as part of the routine monitoring process, this SOP should be followed to conduct the necessary assessment and reporting required by the sponsor."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 1,
                "prefix": 5.2,
                "text": "Assessment of a Serious Breach"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 0,
                "text": "5.2.1  The Trust has delegated authority to the R&D for review of Serious Breaches. It is the R&D's responsibility to assess the potential impact of the breach on patient safety and data integrity to determine whether it qualifies as a serious breach."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 1,
                "prefix": 5.3,
                "text": "Initial Notification of Breach to MHRA"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 0,
                "text": "5.3.1 The R&D office will collate all available information and complete the Notification of Serious Breaches of GCP or the Trial Protocol form (Appendix 2)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 0,
                "text": "5.3.2 The form will be submitted via e-mail to the MHRA within the 7 day reporting period as defined in the regulations."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 0,
                "text": "5.3.3 The R&D Director and R&D Manager will be the contact persons for all correspondence with the MHRA."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 1,
                "prefix": 5.4,
                "text": "Provision of Additional Information to the MHRA"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 0,
                "text": "5.4.1 Once the initial notification has been submitted to the MHRA, the R&D Office will review the breach in full to identify the extent of the breach and continue to update the MHRA with new information."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 0,
                "text": "5.4.2 The Chief Investigator/R&D Office will compile a project report for submission to the MHRA. The project report will include:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 0,
                "text": "1) Full title of trial, ethics approval number, EudraCT number, version number, date of commencement"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 0,
                "text": "2) Name of Chief Investigator"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 0,
                "text": "3) List of Sites"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 0,
                "text": "4) Number of subjects recruited"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 0,
                "text": "5) Brief description of the trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 0,
                "text": "6) Summary of the breach including rationale"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 0,
                "text": "7) Summary of actions taken"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 0,
                "text": "8) Assessment of impact of breach to subject/participant safety"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 0,
                "text": "9) Assessment of the scientific integrity of trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 0,
                "text": "10) Statement from Chief Investigator (if not the person completing the report)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 0,
                "text": "5.4.3 If the incident involves other departments such as pharmacy, then departmental specific (e.g. pharmacy) assessments for point 8 and 9 should be performed. For the assessment of scientific integrity of the trial, the CI of the study should liaise with the named statistician on the trial to complete the data integrity assessment and provide supporting documentation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 0,
                "text": "5.4.4 The R&D Office will review the project report and submit to the MHRA."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 0,
                "text": "5.4.5 The MHRA may request additional information such as a copy of the protocol, ethics application, SOPs etc. The R&D Office will liaise with the study team to obtain additional documents and submit them to the MHRA."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 107,
            "data": {
                "is_heading": 1,
                "prefix": 5.5,
                "text": "Other Reporting Requirements and Implementing Corrective and Preventative Action (CAPA)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 0,
                "text": "5.5.1 Any possible serious breach may also require reporting to the Trust's risk management team in accordance with Trust policy. R&D Office shall make recommendations to the study team about where further reporting requirements apply."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 109,
            "data": {
                "is_heading": 0,
                "text": "5.5.2 The R&D Office shall also ensure that details of the breach are reported to the Trust R&D Advisory Group (Ref: Escalation Plan)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 110,
            "data": {
                "is_heading": 0,
                "text": "5.5.3 The breach may also require reporting to the ethics committee if it is in breach of the ethical conditions of study approval."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 0,
                "text": "5.5.4 The R&D Office will work with the study team to devise a formal plan of Corrective And Preventative Action (CAPA) to address the breach. The CAPA should be submitted to the MHRA in the final report."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 0,
                "text": "5.5.5 Depending on the initial assessment of seriousness and impact, the R&D Office may carry out a full audit of the trial and general trial management systems and procedures."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "RELATED DOCUMENTS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Standard Operating Procedures Working Group Terms of Reference"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Membership of Standard Operating Procedures Working Group"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 116,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol, MHRA."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 117,
            "data": {
                "is_heading": 1,
                "text": "\u25cf Notification of Serious Breach of Good Clinical Practice or Trial Protocol (form)- Please visit the MHRA  website to download the latest MHRA Serious Breach Notification Form"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "REFERENCES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 119,
            "data": {
                "is_heading": 0,
                "text": "The Medicines for Human Use (Clinical Trials) (2004) regulations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "EQUALITY IMPACT ASSESSMENT"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 121,
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "Mid Essex Hospital Services NHS Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals. (Refer to Appendix 4)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 122,
            "data": {
                "is_heading": 1,
                "text": "Appendix 1: Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 123,
            "data": {
                "is_heading": 1,
                "text": "Adverse Event (AE) -  Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 124,
            "data": {
                "is_heading": 1,
                "text": "Case Record Form (CRF) - A printed, optical, or electronic document designed to record all of the protocol required information to be reported to the sponsor on each trial subject."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 125,
            "data": {
                "is_heading": 1,
                "text": "Chief Investigator (CI) -  The person who takes overall responsibility for the design, conduct and reporting of a study if it is at one site; or if the study involves researchers at more than one site, the person who takes primary responsibility for the design conduct and reporting of the study whether or not that person is an Investigator at any particular site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 126,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial - Any investigation in human subjects, other than a non-interventional trial intended to discover or verify the clinical, pharmacological or other pharmacodynamic effects of one or more medicinal product or to identify any adverse reactions to one or more such products and to study absorption, distribution metabolism and excretion in one of more such products with the object of ascertaining the safety or efficacy of those products."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 127,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial Authorisation (CTA) -  Regulatory approval issued by a Competent Authority to conduct a clinical trial within a Member State."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 128,
            "data": {
                "is_heading": 1,
                "text": "Delegated Individual (DI) - An individual delegated by the PI to carry out their task(s)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 129,
            "data": {
                "is_heading": 1,
                "text": "Good Clinical Practice (GCP) - The principles of Good Clinical Practice in Clinical Trials as set down in Articles 2-5 of the GCP Directive and implemented in the UK by Schedule 1 of the Medicines for Human Use (Clinical Trials) Regulations 2004 (S.I.2004/1031) as amended by S.I. 2006/1928."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 130,
            "data": {
                "is_heading": 0,
                "text": "Good Clinical Practice is a set of internationally recognised ethical and scientific quality requirements which must be observed for designing, conducting, recording and reporting clinical trials that involve the participation of human subjects."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 131,
            "data": {
                "is_heading": 1,
                "text": "Honorary Research Contract (HRC) - HRCs are required for researchers who are not employees of the NHS and whose activities could have a foreseeable and direct impact on patient care."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 132,
            "data": {
                "is_heading": 1,
                "text": "International Conference on Harmonisation (ICH) -  International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use is a joint initiative involving both regulators and research-based industry focusing on the technical requirements for medicinal products containing new drugs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 133,
            "data": {
                "is_heading": 1,
                "text": "Investigational Medicinal Products (IMP) -  A pharmaceutical form of an active substance or placebo being tested, or used as a reference in a clinical trial. This includes a medicinal product which has a marketing authorisation but is, for the purposes of the trial -"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 134,
            "data": {
                "is_heading": 0,
                "text": "(a) used or assembled (formulated or packaged) in a way different from the form of the product authorised under the authorisation,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 135,
            "data": {
                "is_heading": 0,
                "text": "(b) used for an indication not included in the summary of product characteristics under the authorisation for that product, or"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 136,
            "data": {
                "is_heading": 0,
                "text": "(c) used to gain further information about the form of that product as authorised under the authorisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 137,
            "data": {
                "is_heading": 1,
                "text": "Principal Investigator (PI) - The leader responsible for a team of individuals conducting a study at a (participating) site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 138,
            "data": {
                "is_heading": 1,
                "text": "Letter of Access - Letters of access enable NHS employees or staff with an honorary clinical contract (e.g. clinical academics) with one NHS organisation to conduct research in another NHS organisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 139,
            "data": {
                "is_heading": 1,
                "text": "Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR) - Any untoward medical occurrence or effect that at any dose results in:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 140,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Death"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 141,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Is life-threatening*"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 142,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Requires hospitalisation or prolongation of existing hospitalisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 143,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Results in persistent or significant disability or incapacity"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 144,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Is a congenital anomaly or birth defect"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 145,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Is an important medical event"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 146,
            "data": {
                "is_heading": 0,
                "text": "* \u201clife-threatening\u201d refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 147,
            "data": {
                "is_heading": 1,
                "text": "Statutory Instrument (SI) - Legal means of implementation of EU Clinical Trials Directive into UK law. SI 1031 (2004), subsequently amended by SI 1928 (2006), SI 2984 (2006), SI 941 (2008) and SI 1184 (2009)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 148,
            "data": {
                "is_heading": 1,
                "text": "The Medicines & Healthcare products Regulatory Agency (MHRA) - The government agency which is responsible for ensuring that medicines and medical devices work, and are acceptably safe."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 149,
            "data": {
                "is_heading": 0,
                "text": "The MHRA can also be defined as:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 150,
            "data": {
                "is_heading": 0,
                "text": "MHRA (Medicines) is the competent authority for the UK in relation to the EU Directive and the Clinical Trials Regulations. MHRA (Devices) is the competent authority for the UK in relation to the Medical Devices Regulations 2002."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 151,
            "data": {
                "is_heading": 1,
                "prefix": 2004.0,
                "text": "The Regulations - Medicines for Human Use (Clinical Trial) Regulations 2004 transposed the EU Clinical Trials Directive into UK legislation, as Statutory Instrument 2004 no 1031. This became  effective  on  the  1st  May   An amendment to  implement  Directive 2005/28/EC was made to the Regulations as Statutory Instrument 2006 no 1928."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 152,
            "data": {
                "is_heading": 1,
                "text": "Trial Master File - The Trial Master File (TMF) will be held at the principal site by the sponsor, Chief Investigator or at the co-ordinating Centre. The TMF should contain all essential documents defined as documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. A Trial Master File should be set up at the beginning of a trial and maintained up-to-date throughout the trial until trial conclusion."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 153,
            "data": {
                "is_heading": 1,
                "text": "For trials currently running, it is recommended that Section 8 of the ICH-GCP Guideline is followed as guidance in order to meet statutory requirements. However, some of the documents listed may not be available or applicable in many non-commercial trials. The appropriate documentation will vary according to the trial and sponsor requirements."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 154,
            "data": {
                "is_heading": 1,
                "text": "Appendix 2: Potential GCP Breach/ Protocol Violation Form"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 155,
            "data": {
                "is_heading": 1,
                "text": "Notification of Potential Serious Breaches of Good Clinical Practice or the Trial Protocol Please complete this notification form and submit to R&D Office"
            }
        },
        {
            "type": "table",
            "sequence_num": 156,
            "data": {
                "num_rows": 12,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Name of person reporting potential serious breach:"
                    },
                    {
                        "text": "Site:"
                    },
                    {
                        "text": "Contact Details: Name: Site: Telephone Number: Email:"
                    },
                    {
                        "text": "Date Breach Identified by Site:"
                    },
                    {
                        "text": "Date Breach Notified to Sponsor:"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Details of related study: Study title: EudraCT:"
                    },
                    {
                        "text": "Report: Tick appropriately"
                    },
                    {
                        "text": "Initial Follow-up Report \u2610 Report \u2610"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "\u2610"
                    },
                    {
                        "text": "\u2610"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "\u2610"
                    },
                    {
                        "text": "\u2610"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "\u2610"
                    },
                    {
                        "text": "\u2610"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "\u2610"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 157,
            "data": {
                "num_rows": 3,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 158,
            "data": {
                "num_rows": 3,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Please list all known information about the potential breach (You do not need to wait for all information to be collected before submission of this form to the Sponsor. Updates are"
                    },
                    {
                        "text": "Nature of Violation/ Deviation:"
                    },
                    {
                        "text": "Response to violation: Was the subject taken off trial as a result of this violation? Have any actions been implemented by site in response to the violation?"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 159,
            "data": {
                "is_heading": 1,
                "text": "Potential Serious Breach Notification Form completed by:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 160,
            "data": {
                "is_heading": 0,
                "text": "Signature: \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026Date: \u2026\u2026\u2026\u2026\u2026\u2026\u2026.. Name & Position: \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 161,
            "data": {
                "is_heading": 1,
                "text": "Appendix 3: Examples of Serious Breaches"
            }
        },
        {
            "type": "table",
            "sequence_num": 162,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Category:"
                    },
                    {
                        "text": "Issue:"
                    },
                    {
                        "text": "Would MHRA have expected this case to be notified?"
                    },
                    {
                        "text": "IMP"
                    },
                    {
                        "text": "Dosing errors reported: A subject was dosed with the incorrect IMP administered via the incorrect route (the IMP used was from a completely different clinical trial to the one the subject was recruited to A subject was dosed with IMP from the incorrect treatment arm. In addition, some months later, the subjects in an entire cohort were incorrectly dosed with IMP three times daily when they should have been dosed once daily One subject was administered additional doses of IMP. The subject was given instructions to take higher doses of IMP than what was stipulated in the protocol. The subject experienced a severe adverse event as a result A subject took IMP that had expired two days ago. The IMP was stable and the subject did not experience any adverse events and this issue was not likely to affect the data credibility of the trial Due to an interactive response technologies (IRT) malfunction 50% of subjects assigned to one arm were unblinded in a blinded trial, furthermore this information was submitted to all trial staff at all investigator sites participating in the trial"
                    },
                    {
                        "text": "Yes, there was significant potential to impact the safety or the rights of trial subjects Yes, There was impact on the safety or physical or mental integrity of trial subjects or on the scientific value of the trial. This issue was systematic and persistence leading to a breach of the Regulation and the trial protocol. The issue persisted despite the implementation of a corrective and preventative action plan Yes, there was impact on the safety of trial subjects and on the scientific value of the trial No, there was no impact on the safety or physical or mental integrity of the trial subject or on the scientific value of the trial. In addition, the assessment of the breach identified this as a single episode and a detailed corrective and preventative action plan was implemented Yes, this could potentially affect the safety of trial subjects, and this was a systematic issue. It also impacts the robustness and reliability of the data generated"
                    },
                    {
                        "text": "Temperatur e monitoring"
                    },
                    {
                        "text": "IMP temperature excursions reported"
                    },
                    {
                        "text": "Yes, if the situation was not managed and subjects were dosed with IMP assessed as unstable which resulted in harm/potential harm of subjects. No, if the excursions had been managed appropriately e.g. IMP was moved to alternative location/quarantined as necessary and an assessment (by qualified personnel) illustrated that there was no impact on subject safety and data integrity, and stability data showed it was stable."
                    },
                    {
                        "text": "IRT issues"
                    },
                    {
                        "text": "Multiple issues with the IRT system across several clinical trials leading to the dispensing of expired IMP and a shortage of IMP at investigator sites in time of subject visits"
                    },
                    {
                        "text": "Yes, there was impact on the safety of trial subjects ad this issue persisted leading to a constant breach of the Regulation or the trial protocol, despite implementation of a corrective and preventative action plan"
                    },
                    {
                        "text": "Potential Fraud"
                    },
                    {
                        "text": "On two separate occasions the sponsor identified issues with the same organisation. First with consenting and then with potential irregularities in recruitment and consenting. However, there was not unequivocal evidence of fraud at the time of reporting. One of the studies involved paediatric subjects"
                    },
                    {
                        "text": "Yes, this subsequently led to enforcement action against the organisation in question"
                    },
                    {
                        "text": "Source Data"
                    },
                    {
                        "text": "Concerns were raised during monitoring visits about changes to source data for a number of subjects in a trial, which subsequently made subjects eligible with no explanation in the subject notes. An audit was carried out by the sponsor and other changes to source data were noted without explanation, potential impacting on data integrity. Follow-up reports confirmed the sponsor concerns over consenting and data changes made to source without an adequate written explanation"
                    },
                    {
                        "text": "Yes, and this needs to be reported when the concerns were raised. Note: not all information was provided in the original notification, the sponsor provided follow up updates"
                    },
                    {
                        "text": "Emergency unbinding"
                    },
                    {
                        "text": "A clinical trial subject attended the hospital emergency department, that attempted to contact the hospital (using the phone number listed on the emergency card issued to the subject) in order to break the unblinding code. Pharmacy was unable to code break in a timely manner, as a result the subject withdrew from the clinical trial feeling unhappy that the pharmacy was not available in an emergency situation"
                    },
                    {
                        "text": "Yes, as this had significant potential to harm the subject if unblinding would have affected the course of the treatment"
                    },
                    {
                        "text": "Sample processing"
                    },
                    {
                        "text": "A cohort had invalid blood samples as they were processed incorrectly. As a result one of the secondary endpoints could not be met. Therefore, a substantial modification was required to recruit more subjects to meet the endpoint"
                    },
                    {
                        "text": "Yes, subjects were dosed unnecessarily as a result of this error"
                    },
                    {
                        "text": "Protocol compliance"
                    },
                    {
                        "text": "Subject safety was compromised because repeat electrocardiograms (ECGs) were not performed, as required by the protocol. The ECGs were required as part of the safety"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 163,
            "data": {
                "num_rows": 2,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": "monitoring due to the pharmacology of the IMP. Also, there was inadequate quality control (QC) of the interim safety reports used for dose escalation which has potential for stopping criteria to be missed if adverse events (AEs) were not transcribed from the source to the safety report. Investigator site failed to reduce or stop trial medication, in response to certain laboratory parameters, as required by the protocol. This occurred with several subjects over a one year period, despite identification by the monitor of the first two occasions. Minor visit date deviation. A common deviation in clinical trials. According to the protocol, a brain CT scan should be performed in the selection visit to exclude brain metastasis (exclusion criteria). The site used a previous version of the protocol where the CT scan wasn't required so 6 patients out of 10 were included without brain CT"
                    },
                    {
                        "text": "Yes Yes, subjects were exposed to an increased risk of thrombosis No, a minor protocol deviation, which does not meet the criteria for notification Yes, if this had an impact on patient safety"
                    },
                    {
                        "text": "SAE reporting"
                    },
                    {
                        "text": "The investigator failed to report a single serious adverse event (SAE) as defined in the protocol (re- training provided) The investigator was not clear on the reporting requirements for the trial and was incorrectly classifying events as expected, as they were common events seen with that particular disease The investigator was not documenting all the AEs associated with the trial"
                    },
                    {
                        "text": "No, if this did not result in other trial subjects being put at risk, and if it was not a systematic or persistent problem. In some circumstances, failure to report a SUSAR could have significant impact on trial subjects. Sufficient information and context should be provided for the impact to be assessed adequately Yes, incorrect classification of seriousness criteria, therefore SAEs incorrectly classifies as AEs or under-reporting of large numbers of SUSARs Yes, depending on the type of trial, for example inadequate safety reporting on dose escalation studies may impact on the decision to escalate to the next dose level"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 164,
            "data": {
                "num_rows": 4,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Consent"
                    },
                    {
                        "text": "Patient information leaflet and informed consent updated, but at one trial site this was not relayed to the patients until approximately 2-3 months after approval. More information on the potential consequences of the delay should have been provided."
                    },
                    {
                        "text": "No, if this was not a systematic or persistent problem and if no harm to trial subjects resulted from the delay Yes, if there was a significant impact on the integrity of trial subjects (e.g. there was key safety information not relayed to subjects in a timely manner"
                    },
                    {
                        "text": "Access to data"
                    },
                    {
                        "text": "The investigator would not allow any party access to the patient's notes Loss of data due for example to servers' breakdown"
                    },
                    {
                        "text": "Yes, the data therefore could not be verified. The protocol would usually contain a clause to state that Sponsor representative and Regulatory Authorities will have access to the data, and this is also reflected in the informed consent Yes, clinical trial sponsors and vendor should have agreements in place addressing business continuity and ensuring that clinical trials data are retrievable at any point in time"
                    },
                    {
                        "text": "Randomisat ion/ stratification errors"
                    },
                    {
                        "text": "Patients incorrectly randomised/stratified according to the protocol"
                    },
                    {
                        "text": "Yes, as this will be likely to have a significant impact on the data"
                    },
                    {
                        "text": "DSMB/DM C"
                    },
                    {
                        "text": "The Data and Safety Monitoring Board (DSMB)/Data Monitoring Committees (DMC), which should be implemented according to the protocol and the clinical trial authorisation in a blinded trial, has in fact not been implemented"
                    },
                    {
                        "text": "Yes, the missing implementation of the DSMB/DMC has significant potential to impact the safety of trial subjects"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 165,
            "data": {
                "is_heading": 0,
                "text": "Research & Development Research Staff Training / MEHTSOP058/1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 166,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 167,
            "data": {
                "is_heading": 1,
                "text": "Appendix 4: Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 168,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Research & Development Research Staff Training / MEHTSOP058"
            }
        },
        {
            "type": "table",
            "sequence_num": 169,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "A change in a service to patients"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to an existing policy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to the way staff work"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A new policy"
                    },
                    {
                        "text": "X"
                    },
                    {
                        "text": "Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "New SOP"
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Review"
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and clinicians"
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change? b) If so, with whom?"
                    },
                    {
                        "text": "Refer to pages 1 and 2"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 170,
            "data": {
                "is_heading": 1,
                "text": "Preliminary analysis completed by:"
            }
        },
        {
            "type": "table",
            "sequence_num": 171,
            "data": {
                "num_rows": 1,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Research & Development Manager"
                    },
                    {
                        "text": "Date"
                    },
                    {
                        "text": "July 2019"
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 172,
            "data": {
                "url": "MEHTSOP058 Serious Breaches (Trust Sponsored) 1.0.001.png"
            }
        }
    ]
}